| Name | MAB-CHMINACA |
|---|
| Formal Name | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide ; ADBCHMINACA |
|---|
| SMILES | NC(=O)C(NC(=O)c3nn(CC1CCCCC1)c2ccccc23)C(C)(C)C |
|---|
| InChI Key | ZWCCSIUBHCZKOY-UHFFFAOYAP |
|---|
| InChI Code | InChI=1/C21H30N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-
17)13-14-9-5-4-6-10-14/h7-8,11-12,14,18H,4-6,9-10,13H2,1-3H3,(H2,22,26)(H,23,27) |
|---|
| Description | MAB-CHMINACA is a synthetic cannabinoid designer drug that is structurally similar to ABCHMINACA,
differing by the replacement of the isopropyl group in the 2-amino primary
amide side chain with a tert-butyl group. The single (S)-enantiomer of MAB-CHMINACA is a
high affinity ligand of the CB1 receptor (Ki = 0.289 nM). It was first observed on illicit
Internet drug sites in August of 2014, and has recently been identified in samples of dubious
herbal products. While the physiological and toxicological properties of this compound
have not yet been reported, MAB-CHMINACA, in conjunction with 5-fluoro-ADB, has been
cited in one postmortem examination as exerting toxicity leading to death after a short
interval. |
|---|
Status |
Verified |
|---|
| Submitted | 2015-03-03 |
|---|
| Submitted By | Cayman Chemical
Miami Valley Regional Crime Laboratory, Dayton, Ohio |
|---|
| Published | 2015-06-08 |
|---|
| Contact | Paul D. Kennedy, PhD. at Cayman Chemical |
|---|
| Product Details | Link |
|---|
Monograph |
Download the MAB-CHMINACA Monograph |
|---|
|
|
